You are here

Early Management and Cost - Costs related to early management in cancer

Jeffrey Crawford and René-Jean Bensadoun, recorded at TAO (Transatlantic Oncology meeting), Nov 21-22, 2013

A10 - Friday 16h30

Jeffrey Crawford: Sarcopenia, or muscle wasting, and cancer will be discussed as a general problem in the cancer patient. Sarcopenia strikes about 50% of all patients in some way. This makes them more susceptible for chemotherapy. Just weight or BMI are not reliable indicators for sarcopenia. You can not always clearly see a patient has muscle wasting. Fatigue is the most seen symptom for lung cancer patients and sarcopenia has a large part in this.